Menu
Recruiting NCT07166822

The Role of Mobile Apps in Promoting Cardiovascular Health and Motivation to Exercise During Pregnancy

No phase Interventional Cardiovascular (CV) Risk Exercise

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Experimental group using BumptUp mobile exercise app.
Who it may be relevant to
Registry conditions: Cardiovascular (CV) Risk, Exercise. Basic parameters: 18 years — 45 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The goal of this study is to determine the effectiveness of a mobile exercise app in improving cardiovascular health and motivation to exercise in pregnant women who are healthy, in their 2nd trimester, between 18-45 years age, and do not do exercise currently. The aims of this study are determine i) the effect of a mobile app (BumptUp) to increase motivation to exercise as assessed by questionnaire, and ii) the changes may occur in cardiovascular health outcomes such as increased percent Flow-Mediated Dilation (FMD), Heart Rate Variability (HRV), and decreased Pulse Wave Velocity (PWV) over an 8-week period of intervention. Researchers will compare this to pregnant women who are healthy, in their 2nd trimester, between 18-45 years age, and who will not be using the mobile app (BumptUp) for exercise. Participants who are in the experimental group will be given access to the mobile app (BumptUp) for 8 weeks. Both the control and experimental group will visit the lab for their baseline measurements (study visit 1), followed by two visits at 4 weeks (study visit 2) and 8 weeks (study visit 3) to have their heart rate variability, arterial stiffness (PWV), and vascular function (FMD) assessed. At each study visit, blood pressure, heart rate, height, and weight will also be measured. Additionally, at all three study visits, participants will fill out a questionnaire to determine motivation to exercise.

Interventions

  • Behavioral Experimental group using BumptUp mobile exercise app
    This BumptUp app has been developed specifically for pregnancy with safety and screening feature. This intervention will be unique since the researchers will evaluate the cardiovascular health outcomes following the 8 weeks of intervention.

Primary outcome measures

  • Flow mediated dilation [Time frame: 8 weeks of intervention period]
Secondary outcome measures (1)
  • Arterial stiffness [Time frame: 8 weeks]

Eligibility criteria

Inclusion criteria

  • Age: 18-45 years.
  • Pregnant women who are 20-24 weeks pregnant at enrollment
  • Sedentary, as defined by completing less than 90 minutes of exercise each week.
  • Generally healthy, uncomplicated pregnancies.
  • Free of physical limitations that may interfere with alterations in daily physical activity levels.
  • Single gestation.
  • Have a smartphone
  • Under the routine medical care of an obstetrician or certified nurse midwife during their current pregnancy.
  • Women speaking English.

Exclusion criteria

  • Physician diagnosed cardiovascular/ vascular complications (heart disease, high blood pressure, Raynaud's phenomenon etc.)
  • Physician diagnosed metabolic diseases (diabetes, hypothyroidism)
  • Musculoskeletal injuries (broken bones, back pain, ankle sprain, muscle pull, etc.)
  • Medications that may impact blood vessel function such as hypertension medication (Angiotensin converting enzyme inhibitor, Angiotensin receptor blocker, Calcium channel blocker, beta blocker), lipid lowering agents (statins), Nitrates, steroids, etc.
  • Complications associated with pregnancy that would be exacerbated by exercise such as lung disease, persistent spotting/bleeding or Placental Previa, premature labor, ruptured membranes, evidence of intrauterine growth restriction, pregnancy induced hypertension or pre-eclampsia, uncontrolled epileptic fits/seizures.
  • Smoking within the previous 3 months.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Other

Study locations

United States · 1 center
  • Old Dominion University — Norfolk

Identifiers

NCT: NCT07166822 · FF2

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗